Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 21:00:00 25/06/2024 BST			5-day change	1st Jan Change
19.19 ^USD	+4.24%		+14.43%	+12.35%

06-17	Declaration of Voting Results by TG Therapeutics	CI
06-17	Declaration of Voting Results by TG Therapeutics	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	04-18	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	02-29	MT
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	02-05	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	01-11	MT
B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating	20/10/23	MT
JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating	07/08/23	MT
Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16	02/08/23	MT
B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating	02/08/23	MT
HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating	01/08/23	MT
Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating	24/07/23	MT
Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating	02/05/23	MT
B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating	02/05/23	MT
HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating	14/04/23	MT
B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating	11/04/23	MT
Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating	07/02/23	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating	24/01/23	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating	30/12/22	MT
Goldman Sachs Adjusts Price Target on TG Therapeutics to $6 From $4, Maintains Sell Rating	30/12/22	MT
B. Riley Boosts Price Target on TG Therapeutics to $23 From $17, Keeps Buy Rating	30/12/22	MT
BofA Raises Price Target on TG Therapeutics to $6 From $5, Maintains Underperform Rating	29/12/22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Analyst Reco.

Filters